Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy CEL-SCI stock

Learn how to easily invest in CEL-SCI stock.

CEL-SCI is a biotechnology business based in the US. CEL-SCI shares (CVM) are listed on the NYSE MKT and all prices are listed in US Dollars.

How to buy CEL-SCI stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – CVM. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Best for beginners

Finder Award


  • Easy to use platform with $0 stock trading & no annual fees
  • Social trading allows you to copy popular portfolios
  • FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100

Promoted for options trading


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+

CEL-SCI stock price (NYSE MKT: CVM)

Use our graph to track the performance of CVM stocks over time.

CEL-SCI shares at a glance

Information last updated 2023-03-17.
Latest market close$2.24
52-week range$1.88 - $5.42
50-day moving average $2.69
200-day moving average $3.34
Wall St. target price$10.50
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.84

Buy CEL-SCI stocks from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 7 of 7
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Award
Stocks, Options, ETFs, Cryptocurrency
FINDER EXCLUSIVE: Get a guaranteed $15 bonus
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency, Futures
Get $100 - $2,000
when you you open and fund an account with $5,000 to $100,000+
Highly commended for Best Derivatives Trading Platform award.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, ETFs, Cryptocurrency, Alternatives, Treasury Bills
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Diversify your portfolio by trading stocks, ETFs, T-Bills, crypto, rare collectibles and more.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs, Treasury Bills
Get $50 - $700
when you open and fund an account with $10,000 - $250,000+
Stocks, Bonds, Options, Mutual funds, ETFs, Futures
Get up to $600 or more
when you open and fund a new account.
E*TRADE offers commission-free stocks, access to mutual funds and advanced trading tools. Other fees apply.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy CEL-SCI stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

CEL-SCI price performance over time

Historical closes compared with the close of $2.24 from 2023-03-20

1 week (2023-03-14) -8.94%
1 month (2023-02-21) -22.49%
3 months (2022-12-21) 8.21%
6 months (2022-09-21) -35.82%
1 year (2022-03-21) -48.51%
2 years (2021-03-19) -87.34%
3 years (2020-03-20) 11.95
5 years (2018-03-21) 45.45%

CEL-SCI financials

Revenue TTM $28,558
Gross profit TTM $-25,355,346
Return on assets TTM -38.16%
Return on equity TTM -94.61%
Profit margin 0%
Book value $0.61
Market capitalisation $101.5 million

TTM: trailing 12 months

CEL-SCI share dividends

We're not expecting CEL-SCI to pay a dividend over the next 12 months.

Have CEL-SCI's shares ever split?

CEL-SCI's shares were split on a 1:25 basis on 14 June 2017. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your CEL-SCI shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for CEL-SCI shares which in turn could have impacted CEL-SCI's share price.

CEL-SCI share price volatility

Over the last 12 months, CEL-SCI's shares have ranged in value from as little as $1.88 up to $5.42. A popular way to gauge a stock's volatility is its "beta".

CVM.US volatility(beta: 1.71)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while CEL-SCI's is 1.7127. This would suggest that CEL-SCI's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

CEL-SCI overview

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 product candidates for the treatment of rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia. .

Frequently asked questions

What percentage of CEL-SCI is owned by insiders or institutions?
Currently 3.88% of CEL-SCI shares are held by insiders and 13.45% by institutions.
When does the fiscal year end for CEL-SCI?
CEL-SCI's fiscal year ends in September.
Where is CEL-SCI based?
CEL-SCI's address is: 8229 Boone Boulevard, Vienna, VA, United States, 22182
What is CEL-SCI's ISIN number?
CEL-SCI's international securities identification number is: US1508376076
What is CEL-SCI's CUSIP number?
CEL-SCI's Committee on Uniform Securities Identification Procedures number is: 150837409

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site